High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: A meta-analysis

International Journal of Infectious Diseases

Volumn 17, Issue 2, 2013, Pages

  Jacob, Jesse T ^a   DiazGranados, Carlos A ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

Bacteremia; Methicillin resistant Staphylococcus aureus; Microbial sensitivity testing; Mortality; Vancomycin

Indexed keywords

VANCOMYCIN;

ARTICLE; BACTEREMIA; BROTH DILUTION; COCHRANE LIBRARY; HUMAN; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OUTCOME ASSESSMENT; PUBLICATION; SENSITIVITY ANALYSIS;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84873417926     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.08.005     Document Type: Article

References (53)

1. Moellering R.C. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006, 42(Suppl 1):S3-S4.
2. Ploy M.C., Grelaud C., Martin C., de Lumley L., Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998, 351:1212.
3. US Centers for Disease Control and Prevention. CDC reminds clinical laboratories and healthcare infection preventionists of their role in the search and containment of vancomycin-resistant Staphylococcus aureus (VRSA). Atlanta, GA: CDC; 2011. Available at: (accessed April 24, 2011). http://www.cdc.gov/HAI/settings/lab/vrsa_lab_search_containment.html
4. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16 2006, CLSI, Wayne, PA.
5. Tenover F.C., Moellering R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215.
6. Hageman J.C., Liedtke L.A., Sunenshine R.H., Strausbaugh L.J., McDonald L.C., Tenover F.C. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006, 43:e42-e45.
7. Liao C.H., Chen S.Y., Huang Y.T., Hsueh P.R. Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an Emergency Department of a medical centre in Taiwan. Int J Antimicrob Agents 2008, 32:326-332.
8. Crompton J.A., North D.S., Yoon M., Steenbergen J.N., Lamp K.C., Forrest G.N. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. J Antimicrob Chemother 2010, 65:1784-1791.
9. Maclayton D.O., Suda K.J., Coval K.A., York C.B., Garey K.W. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006, 28:1208-1216.
10. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., Schentag J.J., Forrest A., Moellering R.C. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004, 38:1700-1705.
11. Neoh H.-M., Hori S., Komatsu M., Oguri T., Takeuchi F., Cui L., et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 2007, 6:13.
12. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
13. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
14. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
15. Review Manager. 5.1 ed. Copenhagen: The Nordic Cochrane Centre, The Cochrane Col laboration; 2008.
16. Choi E.Y., Huh J.W., Lim C.M., Koh Y., Kim S.H., Choi S.H., et al. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 2011, 37:639-647.
17. Ferry T., Uckay I., Vaudaux P., Francois P., Schrenzel J., Harbarth S., et al. Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. Eur J Clin Microbiol Infect Dis 2010, 29:171-180.
18. Haque N.Z., Zuniga L.C., Peyrani P., Reyes K., Lamerato L., Moore C.L., et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010, 138:1356-1362.
19. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
20. Kullar R., Davis S.L., Levine D.P., Rybak M.J. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011, 52:975-981.
21. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
22. Musta A.C., Riederer K., Shemes S., Chase P., Jose J., Johnson L.B., et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009, 47:1640-1644.
23. Price J., Atkinson S., Llewelyn M., Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009, 48:997-998.
24. Wang J.L., Wang J.T., Sheng W.H., Chen Y.C., Chang S.C. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC=2mg/l, by the broth microdilution method. BMC Infect Dis 2010, 10:159.
25. Lewis T., Chaudhry R., Nightingale P., Lambert P., Das I. Methicillin-resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK. Int J Infect Dis 2011, 15:e131-e135.
26. Neuner E.A., Casabar E., Reichley R., McKinnon P.S. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2010, 67:228-233.
27. Lewis E., Welsh K., Abbot A., Gardiner J., Wanger A., Armitige L., et al. Risk factors for the failure of vancomycin in the treatment of MRSA bacteremia. Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America Joint Meeting 2008.
28. Swami A., de Sanctis J., Gerasymchuk L., Sawarynski K., Powell K., Robinson-Dunn B., et al. Clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia. Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America Joint Meeting 2008.
29. Wilhelm K., Patel G., Tahera L., Kelly M., Cooper T. Vancomycin: the impact of MIC on clinical outcomes in MRSA bacteremia and pneumonia. Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America Joint Meeting 2008.
30. Lustberg M., Goff D., Pancholi P., Mangino J. Outcomes in patients with MRSA bacteremia and reduced susceptibility to vancomycin. Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America Joint Meeting 2008.
31. Moore C., Cheema F., Chua T., Perri M., Davis S., Donabedian S., et al. Epidemiology and outcomes of vancomycin treatment for MRSA bacteremia in an urban tertiary healthcare system: preliminary results. Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America Joint Meeting 2008.
32. Yamaki J., Wong-Beringer A. Predicting vancomycin susceptibility of infected MRSA strains based on clinical, epidemiological, and microbiologic variables. Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America Joint Meeting 2008.
33. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 34:1481-1490.
34. Kalil A.C., Murthy M.H., Hermsen E.D., Neto F.K., Sun J., Rupp M.E. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010, 38:1802-1808.
35. Fowler V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
36. Rubinstein E., Lalani T., Corey G.R., Kanafani Z.A., Nannini E.C., Rocha M.G., et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 2010, 52:31-40.
37. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
38. Holmes N.E., Turnidge J.D., Munckhof W.J., Robinson J.O., Korman T.M., O'Sullivan M.V., et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011, 204:340-347.
39. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R., Craig W., Billeter M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
40. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:e18-e55.
41. Etest® package, insert Solna 2003, AB bioMérieux, Sweden.
42. van Hal S.J., Lodise T.P., Paterson D.L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012, 54:755-771.
43. Keel R.A., Sutherland C.A., Aslanzadeh J., Nicolau D.P., Kuti J.L. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn Microbiol Infect Dis 2010, 68:326-329.
44. Swenson J.M., Anderson K.F., Lonsway D.R., Thompson A., McAllister S.K., Limbago B.M., et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol 2009, 47:2013-2017.
45. Bae I.G., Federspiel J.J., Miro J.M., Woods C.W., Park L., Rybak M.J., et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009, 200:1355-1366.
46. Lalueza A., Chaves F., San Juan R., Daskalaki M., Otero J.R., Aguado J.M. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia?. J Infect Dis 2009, 201:311-312. author reply 312-3.
47. Schweizer M.L., Furuno J.P., Sakoulas G., Johnson J.K., Harris A.D., Shardell M.D., et al. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob Agents Chemother 2010, 55:1082-1087.
48. Takesue Y., Nakajima K., Takahashi Y., Ichiki K., Ishihara M., Wada Y., et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 mug/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother 2011, 17:52-57.
49. van Hal S.J., Wehrhahn M.C., Barbagiannakos T., Mercer J., Chen D., Paterson D.L., et al. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol 2011, 49:1489-1494.
50. Huang W.C., Lee C.H., Liu J.W. Clinical characteristics and risk factors for mortality in patients with meningitis caused by Staphylococcus aureus and vancomycin minimal inhibitory concentrations against these isolates. Journal Microbiol Immunol infect=Wei mian yu gan ran za zhi 2010, 43:470-477.
51. Hsu D.I., Hidayat L.K., Quist R., Hindler J., Karlsson A., Yusof A., et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008, 32:378-385.
52. Moise P.A., Sakoulas G., Forrest A., Schentag J.J. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007, 51:2582-2586.
53. Yoon Y.K., Kim J.Y., Park D.W., Sohn J.W., Kim M.J. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrobial Chemother 2010, 65:1015-1018.